{
    "ticker": "MGC",
    "name": "MGC Pharmaceuticals Ltd",
    "description": "MGC Pharmaceuticals Ltd is a biopharmaceutical company focused on the research, development, and commercialization of cannabinoid-based products for the treatment of various medical conditions. Established in 2015, the company is dedicated to providing high-quality, evidence-based treatments derived from cannabis. MGC Pharma operates in the rapidly evolving medical cannabis sector and is committed to advancing the science of cannabinoid therapies through rigorous clinical trials and research. The company has developed a portfolio of proprietary products, including formulations for epilepsy, multiple sclerosis, and other chronic conditions. MGC Pharmaceuticals aims to bridge the gap between traditional pharmaceutical approaches and innovative cannabinoid-based treatments, ensuring patient safety and efficacy. With operations in Europe, Australia, and the United Kingdom, MGC is strategically positioned to leverage the growing acceptance of medical cannabis globally. The company is also focused on expanding its footprint in the global market through partnerships and collaborations with research institutions and healthcare providers. With a strong emphasis on compliance and quality assurance, MGC Pharmaceuticals is dedicated to ensuring that its products meet the highest standards of safety and efficacy, ultimately improving the quality of life for patients worldwide.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Perth, Australia",
    "founded": "2015",
    "website": "https://mgcpharma.com.au",
    "ceo": "Roby Zomer",
    "social_media": {
        "twitter": "https://twitter.com/MGCPharma",
        "linkedin": "https://www.linkedin.com/company/mgc-pharmaceuticals-ltd/"
    },
    "investor_relations": "https://mgcpharma.com.au/investor-relations/",
    "key_executives": [
        {
            "name": "Roby Zomer",
            "position": "CEO"
        },
        {
            "name": "Dr. Igor Kovacevic",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Cannabinoid Products",
            "products": [
                "CannEpil",
                "Zamzam"
            ]
        }
    ],
    "seo": {
        "meta_title": "MGC Pharmaceuticals Ltd | Biopharmaceuticals & Cannabinoid Therapies",
        "meta_description": "Explore MGC Pharmaceuticals, a leader in cannabinoid-based treatments. Discover innovative products and commitment to improving patient health through science.",
        "keywords": [
            "MGC Pharmaceuticals",
            "Cannabinoid Products",
            "Medical Cannabis",
            "Biopharmaceuticals",
            "Roby Zomer"
        ]
    },
    "faq": [
        {
            "question": "What does MGC Pharmaceuticals specialize in?",
            "answer": "MGC Pharmaceuticals specializes in cannabinoid-based medical products for various health conditions."
        },
        {
            "question": "Who is the CEO of MGC Pharmaceuticals?",
            "answer": "The CEO of MGC Pharmaceuticals is Roby Zomer."
        },
        {
            "question": "Where is MGC Pharmaceuticals headquartered?",
            "answer": "MGC Pharmaceuticals is headquartered in Perth, Australia."
        },
        {
            "question": "What are the key products of MGC Pharmaceuticals?",
            "answer": "MGC Pharmaceuticals' key products include CannEpil and Zamzam."
        },
        {
            "question": "When was MGC Pharmaceuticals founded?",
            "answer": "MGC Pharmaceuticals was founded in 2015."
        }
    ],
    "competitors": [
        "APHA",
        "CGC",
        "CRON"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "JNJ",
        "PFE"
    ]
}